Home›Research›Compare›AOD-9604 vs Sermorelin
Peptide ComparisonAOD-9604 vs Sermorelin
Both are GH / IGF Axis peptides.
AOD-9604
Advanced Obesity Drug 9604
Half-life: 30–60 minutes
197 providers listed
Sermorelin
GHRH 1-29
Half-life: 10–20 minutes
449 providers listed
Sermorelin carries stronger published evidence (RCT, 3 key studies) than AOD-9604 (Animal, 1); both are research compounds.
AOD-9604
Half-life
30–60 minutes
Sermorelin
Half-life
10–20 minutes
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Sermorelin |
| Less frequent dosing (longer half-life) | AOD-9604 |
| Oral administration option | AOD-9604 |
| More provider options (197 vs 449) | Sermorelin |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
AOD-9604
Sermorelin
AOD-9604
Sermorelin
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients…
The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostat…
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodyb…
About AOD-9604
AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.
About Sermorelin
Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
AOD-9604
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Sermorelin
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Sermorelin clinical protocols measure IGF-1 as the primary marker of GH axis response. Fasting glucose and insulin are standard baseline assessments given GH's effect on insulin sensitivity.
Sermorelin
Ipamorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
AOD-9604
Sermorelin
Where to source these peptides
AOD-9604
197 listed
Browse directory →
Providers offeringSermorelin
449 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AOD-9604 vs Sermorelin — Per-mg Price Comparison. Retrieved August 26, 2026, from https://peptidebase.io/peptides/compare/aod-9604/sermorelin